Clinicopathological and Survival Outcomes of Well-Differentiated Thyroid Carcinoma Undergoing Dedifferentiation: A Retrospective Study from FUSCC

Table 5

Clinicopathological factors associated with dedifferentiated components.

Parameters	Dedifferentiated components		value
	PDTC	ATC
Gender			0.013
Male	19 (65.5%)	10 (34.5%)
Female	31 (91.2%)	3 (8.8%)
Age (years)			0.009
<55	28 (93.3%)	2 (6.7%)
≥55	22 (66.7%)	11 (33.3%)
Tumor size (cm)			0.554
≤1	6 (85.7%)	1 (14.3%)
>1	44 (78.6%)	12 (21.4%)
ETE			0.371
No	39 (81.3%)	9 (18.7%)
Yes	11 (73.3%)	4 (26.7%)
DTC subtypes			0.472
PTC	41 (80.4%)	10 (19.6%)
FTC	9 (75.0%)	3 (25.0%)
Dedifferentiated site			0.536
Thyroid	33 (82.5%)	7 (17.5%)
Metastatic site	14 (77.8%)	4 (22.2%)
Thyroid and metastatic site	3 (60.0%)	2 (40.0%)
LNM			0.502
N0	17 (77.3%)	5 (22.7%)
N1	33 (80.5%)	8 (19.5%)
DM			0.570
M0	37 (78.7%)	10 (21.3%)
M1	13 (81.3%)	3 (18.7%)
TNM stage (the 8th edition)			0.142
I-II	37 (84.1%)	7 (15.9%)
III-IV	13 (68.4%)	6 (31.6%)

Bold type indicates statistical significance. PDTC: poorly differentiated thyroid cancer; ATC: anaplastic thyroid cancer; ETE: extrathyroidal extension; PTC: papillary thyroid cancer; FTC: follicular thyroid cancer; LNM: lymph node metastasis; DM: distant metastasis; TNM: tumor-node-metastasis.